Abstract
Data from the WHO Collaborative Study suggest that use of progestagen preparations with therapeutic indications are associated with a significantly increased risk of venous thromboembolism but not stroke or myocardial infarction.
MeSH terms
-
Adult
-
Case-Control Studies
-
Contraceptives, Oral, Synthetic / adverse effects*
-
Female
-
Humans
-
Logistic Models
-
Middle Aged
-
Myocardial Infarction / chemically induced
-
Odds Ratio
-
Progesterone Congeners / adverse effects*
-
Progesterone Congeners / therapeutic use
-
Risk Factors
-
Stroke / chemically induced
-
Thromboembolism / chemically induced*
-
World Health Organization
Substances
-
Contraceptives, Oral, Synthetic
-
Progesterone Congeners